Ever since the estrogen receptor (ER) β was discovered in 1996, we have been trying to
determine its value as a prognostic and/or predictive factor in breast cancer and its potential …

Since 1996 when estrogen receptor β (ERβ) was discovered, much effort has been devoted
to the question of the value of ERβ as a prognostic and/or predictive factor in breast cancer …

More than 10 years have passed since the discovery of the second estrogen receptor,
estrogen receptor β (ERβ). It is now evident that ERα is not the only ER in breast cancer …

Two oestrogen receptors (ERs), ERα and ERβ, have been identified. ERα is by far the better
characterized and is an established predictive marker in breast cancer which influences …

The estrogen receptor (ER)-β isoform has been recently identified to be distinct from ERα
isoform and regulates separate sets of genes, and can exert opposite signaling functions …

The assessment of the estrogen receptor (ER) α and the progesterone receptor (PgR) in
breast cancer tissues is important for discriminating between hormone-dependent and …

The recent discovery of a second estrogen receptor (ER), designated ERβ, raises pressing
questions about its role in estrogen regulation of human breast cancer cells and its …

The discovery of a second estrogen receptor (ER), ERβ, has led to a reevaluation of
estrogen action. The widespread expression of ERβ-like proteins in normal and neoplastic …

The cloning of a second estrogen receptor (ER), ERβ, has prompted a reevaluation of the
role of ERs in breast cancer. The aim of this study was to determine the expression of both …

The estrogen receptor (ER) exists in two forms known as ERα and ERβ. Currently, a clinical
role has only been established for ERα. The primary use of ERα in breast cancer is for …